Merck to pay $688 million to settle Enhance lawsuits -
Vytorin pairs Zetia with the active ingredient of Zocor. Zetia helps block absorption of “bad” LDL cholesterol in the intestines, and Zocor helps. Welcome to the information website for In re Merck & Co. Inc. Vytorin/Zetia. reached a settlement of the Action with Defendants for $215,000,000 in cash the. Drug makers Merck & Co. and Schering-Plough Corp. will pay $41.5 million to settle lawsuits concerning their cholesterol drugs Vytorin and Zetia. The lawsuits.
In re Merck & Co. Inc. Vytorin/Zetia
In re Merck & Co. Inc. Vytorin/Zetia Securities Litigation c/o Epiq Systems, Inc. Settlement Website The Zetia and Vytorin Class Action Lawsuit Settlement and how to submit your claim. Merck's $688M Vytorin Settlement Wins Judge's Nod. Inc. Vytorin/Zetia Securities Litigation, case number -cv-02177, and In re.
Drug Companies Settle Vytorin and Zetia Lawsuits
The settlement, according to plaintiffs attorneys, is one of the top 25. and Schering-Plough fell, and so did prescriptions of Zetia and Vytorin. October 1, 2013 – Court Grants Final Approval of $215 Million Settlement in In re Merck & Co. Inc. Vytorin/Zetia Securities Litigation; Total Recoveries in.
Merck Settles Suits Over Cholesterol Drug - The New York
The drug maker agreed to pay $688 million to settle two lawsuits that. In their heyday, Zetia and Vytorin were heavily promoted by Merck and. Million Settlement – Zetia and Vytorin. Seeger Weiss LLP announced today a $41.5 million settlement with Merck & Co. Inc. and.